For the Culture By The Culture
This week’s Reefer Report Card tracks a familiar pattern in cannabis policy: delay dressed as progress. Federal lawmakers punted again on hemp regulation, states flirted with dismantling legal markets, and patients were left waiting. Oversight weakened, accountability faded, and reform stalled. Another week in weed, graded.
A proposed federal hemp framework is being sold as long overdue clarity for a chaotic market. But beneath the promise of order, the structure reveals rigid caps, unresolved enforcement questions, and a quiet shift of power away from states and smaller producers. We break down what the proposal does, what it avoids, and why the difference matters.
Actor David Krumholtz’s experience with Cannabinoid Hyperemesis Syndrome sparked a backlash that reveals a deeper problem in cannabis culture. This piece examines how rare conditions get weaponized, why defensive reactions backfire, and how patients, veterans, and families are erased when nuance collapses on both sides of the cannabis debate.
As 2025 closes, cannabis reform headlines promised progress while delivering performance. Pot Culture Magazine looks back without celebration, without hype, and without illusions. This year did not resolve prohibition or fix power. It revealed who controls the narrative, who benefits from delay, and why cannabis culture keeps surviving without permission.
Federal officials claim cannabis is moving forward, but Schedule III changes nothing that matters. This investigation breaks down what rescheduling actually does, what it deliberately avoids, and why prohibition logic remains intact. Arrests continue. Markets remain conflicted. Reform language replaces reform action. The system shifts labels while preserving control.
Hospitals increasingly diagnose Cannabinoid Hyperemesis Syndrome without testing the cannabis products involved. This investigation examines how cartridges, edibles, and other cannabis materials are excluded from medical evaluation, despite known contamination risks, leaving patients with diagnoses based on symptoms and self reported use rather than verified evidence.
